Table 3. Metabolic variabilities among the groups treated with DMBA and ALA when compared to normal control.
| # | 1H ppm | Metabolite (↓↑) |
Control vs | ||
|---|---|---|---|---|---|
| DMBA | ALA-0.25 | ALA-0.5 | |||
| 1 | 0.825-0.885 | LDL | *(↑) | *(↑↑) | *(↑↑↑) |
| 2 | 1.205-1.235 | VLDL | *(↑) | *(↑↑) | *(↑↑↑) |
| 3 | 5.245-5.355 | PUFA | *(↑) | *(↑) | *(↑↑↑) |
| 4 | 0.985 | Isoleucine | (↓)# | *(↓↓) | (↓↓↓)# |
| 5 | 7.025, 7.725 | Histidine | *(↑) | *(↑↑) | *(↑↑↑) |
| 6 | 7.405 | Phenylalanine | *(↑) | (↓↓)# | *(↓↓) |
| 7 | 1.455 | Alanine | *(↓) | (↓↓)# | *(↓↓) |
| 8 | 1.695-1.715 | Arginine | *(↑) | (↓↓)# | (↓↓)# |
| 9 | 2.435 | Glutamine | *(↓) | *(↓↓↓) | *(↓↓) |
| 10 | 1.995 | Proline | *(↓) | (↑) | *(↓↓↓) |
| 11 | 3.535 | Glycine | *(↑) | *(↑) | *(↑) |
| 12 | 6.885, 7.175 | Tyrosine | (↑)# | *(↓↓↓) | *(↓↓) |
| 13 | 1.865-1.885 | Citrulline | *(↑) | (↑↑)# | (↑↑↑)# |
| 14 | 3.015 | Creatine | (↑) | *(↓↓) | *(↓↓) |
| 15 | 1.895 | Acetate | (↑)# | *(↓↓) | *(↓↓↓) |
| 16 | 2.025 | NAG | (↑) | *(↓↓↓) | *(↓↓) |
| 17 | 2.115, 2.125 | OAG | (↑)# | *(↓↓) | *(↓↓) |
| 18 | 2.325 | Glutamate | *(↓) | *(↓↓↓) | *(↓↓) |
| 19 | 3.885, 5.215 | Glucose | *(↓) | *(↓) | *(↓) |
| 20 | 3.605 | Myo-Inositol | *(↑) | (↓↓)# | (↓↓↓) |
| 21 | 1.315 | Lactate | (↑) | *(↓↓) | *(↓↓) |
| 22 | 3.185 | Choline | *(↓) | (↓↓)# | *(↓↓) |
| 23 | 5.365 | Allantoin | *(↑) | (↑)# | *(↑) |
| 24 | 8.435 | Formate | *(↑) | *(↑↑) | (↑↑↑)# |
| 25 | 8.825, 9.115 | Trigonelline | *(↑) | (↑↑↑)# | (↑↑)# |
The up and down arrows represent, respectively, increased and decreased metabolite levels. A ↑↑↑/↓↓↓ or ↑↑/↓↓ score was given to the metabolites of the treatment dose which showed ameliorating effects from DMBA towards control. Abbreviations used are as follows: LDL (low density lipoproteins); VLDL (very low density lipoproteins); NAG (N-acetyl glycoprotein); OAG (O-acetyl glycoprotein); PUFA (poly unsaturated fatty acids).
Note-: Symbols * = p-value < 0.05, # = VIP Score < 1.